スタッフ紹介

助教/外来医長森川 賢一

Kenichi Morikawa

専門分野

消化器内科学、肝臓病学、
ウイルス肝炎診断・治療

助教/外来医長　森川 賢一

学歴

1993年3月
愛知県私立東海高等学校卒業
1999年3月
昭和大学医学部卒業
2003年3月
昭和大学大学院医学研究科第二内科学講座医学博士課程修了

職務経歴

1999年5月
昭和大学病院消化器内科　医師
2003年4月
昭和大学医学部第二内科　員外助教
2005年4月
(財)東京都神経科学総合研究所微生物学部門　流動研究員
2006年4月
国立感染症研究所ウイルス第二部　流動研究員　及び　財団法人ヒューマンサイエンス財団　流動研究員
2007年4月
昭和大学医学部第二内科　員外助教　及び　国立感染症研究所ウイルス第二部　協力研究員
2008年1月
昭和大学医学部内科学講座消化器内科学部門　助教　及び　国立感染症研究所ウイルス第二部　協力研究員
2009年8月
Lausanne大学医学部消化器内科　博士研究員
2012年4月
昭和大学医学部内科学講座消化器内科学部門　助教
2014年10月
北海道大学大学院医学研究科内科学講座消化器内科学分野　助教
2015年4月
北海道大学病院消化器内科　助教
2018年4月
北海道大学大学院医学研究院消化器内科学教室助教　助教

所属学会・資格

  • 日本内科学会　認定内科医
  • 日本消化器病学会　専門医・指導医・支部評議員・学会評議員
  • 日本肝臓学会　専門医・指導医・東部会評議員・学会評議員
  • 日本消化器内視鏡学会　専門医・指導医
  • 日本医師会　認定産業医
  • 日本ウイルス学会
  • ヨーロッパ肝臓学会国際会員

受賞歴

  • 2017年 第3回G-PLUS優秀賞
  • 2016年 第6回Hepatology Meeting in Japan 2016 最優秀演題賞
  • 2016年 第25回アジア太平洋肝臓病学会議年次総会（APASL2016）Presidential Award
  • 2014年 Liver Forum in Kyoto研究助成
  • 2014年 日本肝臓学会・冠アワード
  • 2008年 第44回日本肝臓学会総会会長奨励賞
  • 2007年 第4回大正富山アワード
  • 2007年 宮川庚子記念財団研究助成

研究費等

国立研究開発法人日本医療研究開発機構（AMED）

  • 肝炎等克服実用化研究事業　「肝炎ウイルスの感染複製増殖と病原性発現を阻止するための基盤的研究とその応用のための基盤的開発」　研究分担者（2019年度-2021年度）
  • B型肝炎創薬実用化等研究事業　「B型肝炎ウイルスの感染複製増殖機構の解明に関する研究｣　研究分担者（2017年度-2021年度）
  • 肝炎等克服実用化研究事業　「肝炎ウイルスの感染複製増殖と病原性発現を阻止するための基盤的研究」　研究分担者（2016年度-2018年度）

厚生労働省科学研究費補助金

  • B型肝炎創薬実用化等研究事業　「B型肝炎ウイルスの感染複製機構の解明に関する研究｣　研究分担者（2012年度-2016年度）
  • 肝炎等克服実用化研究事業　「肝炎ウイルスの複製増殖および病原性発現機構と薬剤感受性の解析」　研究分担者（2014年度-2015年度）

文部科学省科学研究費補助金

  • 基盤研究（C）　「B型肝炎ウイルス宿主制限因子を標的とした新規抗ウイルス治療の開発」　研究代表者（2020年度-2022年度）
  • 基盤研究（B）　｢肝硬変の組織学的進展・軽快を担う間質微小環境因子の包括的解析｣　研究分担者（2019-2021年度）
  • 基盤研究（C）　｢レポーターアッセイによる新規・大規模抗HBV薬スクリーニング系を用いた薬剤開発｣　研究分担者（2019-2021年度）
  • 基盤研究（C）　「B型肝炎ウイルスcccDNA排除を目指した新規抗ウイルス治療の開発」　研究代表者（2017年度-2019年度）
  • 挑戦的萌芽研究　｢生体高分子シミュレーションによる抗ウイルス薬耐性化仮想アッセイシステムの構築｣　研究分担者（2016年度-2017年度）
  • 基盤研究（C）　｢C末端欠損HBx遺伝子インテグレーションによる肝発癌・悪性化機構の検討｣　研究分担者（2016年度-2018年度）
  • 基盤研究（B）　｢肝硬変の組織病態を修復する新規細胞治療法の探索｣　研究分担者（2016年度-2018年度）
  • 基盤研究（C）　「C型肝炎ウイルスの粒子形成・分泌機構の解明と関与する細胞性因子の解析」　研究代表者（2014年度-2016年度）
  • 若手研究（B）　「C型肝炎ウイルス感染におけるレセプターを含む細胞性因子の関与」　研究代表者（2008年度-2009年度）
  • 基盤研究（B）　「C型肝炎ウイルス培養系による感染増殖効率規定因子の解析と新規治療標的候補の探索」　研究分担者（2006年度-2008年度）
  • 若手研究（B）　「感染性C型肝炎ウイルス粒子の精製と性状の解析」 研究代表者（2006年度-2007年度）
  • 特定領域研究　「感染性C型肝炎ウイルス粒子による肝細胞への遺伝子デリバリーシステムの構築」　研究分担者（2006年度-2007年度）
  • 基盤研究（C）　「C型肝炎ウイルス新規感染培養系における、ウイルスadaptationの解析」　研究分担者（2006年度-2007年度）

業績
（英文のみ）

  1. Koji Ogawa, Takashi Kobayashi, Jun-ichi Furukawa, Hisatoshi Hanamatsu, Akihisa Nakamura, Kazuharu Suzuki, Naoki Kawagishi, Masatsugu Ohara, Machiko Umemura, Masato Nakai, Takuya Sho, Goki Suda, Kenichi Morikawa, Masaru Baba, Ken Furuya, Katsumi Terashita, Tomoe Kobayashi, Manabu Onodera, Takahiro Horimoto, Keisuke Shinada, Seiji Tsunematsu, Izumi Tsunematsu, Takashi Meguro, Tomoko Mitsuhashi, Megumi Hato, Kenichi Higashino, Yasuro Shinohara, Naoya Sakamoto.
    Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis.
    Sci Rep. 2020; 10: 321. Published online 2020 Jan 15. doi: 10.1038/s41598-019-56947-1. PMCID: PMC6962197
  2. Takuya Sho, Goki Suda, Koji Ogawa, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kenichi Morikawa, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Tomoe Kobayashi, Takashi Meguro, Akiyoshi Saga, Takuto Miyagishima, Hideki Yokoo, Toshiya Kamiyama, Akinobu Taketomi, Naoya Sakamoto.
    Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting.
    JGH Open. 2020 Feb; 4(1): 54–60. Published online 2019 Jun 10. doi: 10.1002/jgh3.12209 PMCID: PMC7008153
  3. Ohara M, Suda G, Kimura M, Maehara O, Shimazaki T, Shigesawa T, Suzuki K, Nakamura A, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kobayashi T, Uebayashi M, Takagi R, Yokota I, Shimamura T, Sakamoto N.
    Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people.
    Hepatol Res. 2020 Mar 23. doi: 10.1111/hepr.13499. [Epub ahead of print] PMID: 32202371
  4. Kitagataya T, Suda G, Nagashima K, Katsurada T, Yamamoto K, Kimura M, Maehara O, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Komatsu Y, Hata H, Takeuchi S, Abe T, Sakakibara-Konishi J, Teshima T, Homma A, Sakamoto N.
    Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    J Gastroenterol Hepatol. 2020 Mar 18. doi: 10.1111/jgh.15041. [Epub ahead of print] PMID: 32187734
  5. Sho T, Suda G, Ogawa K, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Yokoo H, Kamiyama T, Taketomi A, Sakamoto N.
    Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.
    JGH Open. 2019 Jun 10;4(1):54-60. doi: 10.1002/jgh3.12209. eCollection 2020 Feb. PMID:32055698
  6. Kawagishi N, Suda G, Kimura M, Maehara O, Shimazaki T, Yamada R, Kitagataya T, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N.
    High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C.
    Hepatol Res. 2020 Feb 5. doi: 10.1111/hepr.13490. [Epub ahead of print] PMID: 32020702
  7. Ogawa K, Kobayashi T, Furukawa JI, Hanamatsu H, Nakamura A, Suzuki K, Kawagishi N, Ohara M, Umemura M, Nakai M, Sho T, Suda G, Morikawa K, Baba M, Furuya K, Terashita K, Kobayashi T, Onodera M, Horimoto T, Shinada K, Tsunematsu S, Tsunematsu I, Meguro T, Mitsuhashi T, Hato M, Higashino K, Shinohara Y, Sakamoto N.
    Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis.
    Sci Rep. 2020 Jan 15;10(1):321. doi: 10.1038/s41598-019-56947-1. PMID:31941930
  8. Hanamatsu H, Nishikaze T, Tsumoto H, Ogawa K, Kobayashi T, Yokota I, Morikawa K, Suda G, Sho T, Nakai M, Miura N, Higashi-No K, Sekiya S, Iwamoto S, Miura Y, Furukawa JI, Tanaka K, Sakamoto N.
    Comparative glycomic analysis of sialyl linkage isomers by sialic acid linkage-specific alkylamidation in combination with stable isotope labeling of α2,3-linked sialic acid residues.
    Anal Chem. 2019 Nov 5;91(21):13343-13348. doi: 10.1021/acs.analchem.9b03617. PMID: 31577134
  9. Sugiura R, Kuwatani M, Nishida M, Hirata K, Sano I, Kato S, Kawakubo K, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Sakamoto N.
    Correlation between Liver Elasticity by Ultrasound Elastography and Liver Functional Reserve.
    Ultrasound Med Biol. 2019 Oct;45(10):2704-2712. doi: 10.1016/j.ultrasmedbio.2019.06.407. PMID: 31300223
  10. Kobayashi T, Ogawa K, Furukawa JI, Hanamatsu H, Hato M, Yoshinaga T, Morikawa K, Suda G, Sho T, Nakai M, Higashino K, Numata Y, Shinohara Y, Sakamoto N.
    Quantifying Protein-Specific N-glycome Profiles by Focused Protein- and Immunoprecipitation-Glycomics.
    J Proteome Res. 2019 Aug 2;18(8):3133-3141. doi: 10.1021/acs.jproteome.9b00232. PMID: 31266306
  11. Suda G, Kimura M, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Maehara O, Shimazaki T, Morikawa K, Natsuizaka M, Ogawa K, Sakamoto N.
    Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to anti-hepatitis C virus drugs.
    Hepatol Res. 2019 Nov;49(11):1275-1285. doi: 10.1111/hepr.13401. PMID: 31261439
  12. Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Kimura M, Maehara O, Shimazaki T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis.
    Hepatol Res. 2019 Nov;49(11):1294-1304. doi: 10.1111/hepr.13399. PMID: 31260579
  13. Izumi T, Sho T, Morikawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Umemura M, Shimazaki T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Kudo Y, Nishida M, Ono K, Baba M, Furuya K, Sakamoto N.
    Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter.
    Hepatol Res. 2019 Oct;49(10):1207-1217. doi：10.1111/hepr.13391. PMID:31219667
  14. Suda G, Hasebe C, Abe M, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Haga H, Ueno Y, Abe K, Takahashi A, Ohira H, Tsukuda Y, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Inoue J, Terasita K, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    J Gastroenterol. 2019 Feb 18. doi: 10.1007/s00535-019-01556-y. [Epub ahead of print] PMID: 30778716
  15. Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, Nakamura A, Ohara M, Izumi T, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Miyoshi H, Sakamoto N.
    Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
    PLoS One. 2018 Dec 21;13(12):e0209615. doi: 10.1371/journal.pone.0209615. eCollection 2018. PMID: 30576386
  16. Suda G, Nakai M, Sho T, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Umemura MOM, Kawagishi N, Baba M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment: A Case Report.
    Intern Med. 2018 Dec 18. doi: 10.2169/internalmedicine.2077-18. [Epub ahead of print] PMID: 30568153
  17. Sho T, Suda G, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Izumi T, Kawagishi N, Baba M, Nakai M, Natsuizka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
    Intern Med. 2018 Nov 19. doi: 10.2169/internalmedicine.1856-18. [Epub ahead of print] PMID: 30449808
  18. Morikawa K, Nakamura A, Shimazaki T, Sakamoto N.
    Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence.
    Drug Des Devel Ther. 2018 Sep 5;12:2749-2756. doi: 10.2147/DDDT.S133697. eCollection 2018. Review.　PMID:　30233138
  19. Ohara M, Ogawa K, Suda G, Kimura M, Maehara O, Shimazaki T, Suzuki K, Nakamura A, Umemura M, Izumi T, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ohnishi S, Sakamoto N.
    L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis.
    Hepatol Commun. 2018 Aug 6;2(8):906-918. doi: 10.1002/hep4.1207. eCollection 2018 Aug. PMID: 30094402
  20. Suda G, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Hasebe C, Abe M, Haga H, Ueno Y, Masakane I, Abe K, Takahashi A, Ohira H, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Kawakami A, Kumagai K, Terasita K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
    J Gastroenterol. 2018 Jul 17. doi: 10.1007/s00535-018-1495-6. [Epub ahead of print] PMID: 30019127
  21. Cai C, Koch B, Morikawa K, Suda G, Sakamoto N, Rueschenbaum S, Akhras S, Dietz J, Hildt E, Zeuzem S, Welsch C, Lange CM.
    Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids.
    Front Immunol. 2018 Apr 12;9:723. doi: 10.3389/fimmu.2018.00723. eCollection 2018. PMID: 29706960
  22. Doi H, Hayashi E, Arai J, Tojo M, Morikawa K, Eguchi J, Ito T, Kanto T, Kaplan DE, Yoshida H.
    Enhanced B-cell differentiation driven by advanced cirrhosis resulting in hyperglobulinemia.
    J Gastroenterol Hepatol. 2018 Feb 10. doi: 10.1111/jgh.14123. [Epub ahead of print] PMID: 29427373
  23. Sho T, Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Uebayashi M, Terashita K, Kobayashi T, Tsunematsu I, Onodera M, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Kawagishi N, Ohara M, Ono Y, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
    Hepatol Res. 2018 Jun;48(7):529-538. doi: 10.1111/hepr.13056. Epub 2018 Feb 15. PMID: 29316051
  24. Suda G, Ogawa K, Morikawa K, Sakamoto N.
    Treatment of hepatitis C in special populations.
    J Gastroenterol. 2018 May;53(5):591-605. doi: 10.1007/s00535-017-1427-x. Epub 2018 Jan 3. Review. PMID: 29299684
  25. Nakai M, Ogawa K, Takeda R, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J, Sho T, Suda G, Morikawa K, Sakamoto N.
    Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis.
    Hepatol Res. 2018 Feb;48(3):　E311-E319. doi: 10.1111/hepr.12988. Epub 2017 Nov 3.　PMID:　28984014
  26. Maehara O, Suda G, Natsuizaka M, Ohnishi S, Komatsu Y, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Shimazaki T, Kimura M, Asano A, Fujimoto Y, Ohashi S, Kagawa S, Kinugasa H, Naganuma S, Whelan KA, Nakagawa H, Nakagawa K, Takeda H, Sakamoto N.
    Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma.
    Carcinogenesis. 2017 Oct 26;38(11):1073-1083. doi: 10.1093/carcin/bgx095. PMID: 28927233
  27. Suda G, Ito J, Nagasaka A, Yamamoto Y, Furuya K, Okamoto M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Ohara M, Kawagishi N, Kimura M, Umemura M, Izumi T, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: a randomized controlled study.
    Hepatol Res. 2018 Feb;48(3):E146-E154. doi: 10.1111/hepr.12938. Epub 2017 Aug 10.　PMID:　28722780
  28. Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ohara M, Izumi T, Umemura M, Ito J, Nakai M, Sho T, Natsuizka M, Morikawa K, Ogawa K, Sakamoto N.
    Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    J Viral Hepat. 2017 Dec;24(12):1098-1106. doi: 10.1111/jvh.12737. PMID: 28632923
  29. Sho T, Nakanishi M, Morikawa K, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J, Nakai M, Suda G, Ogawa K, Chuma M, Meguro T, Nakamura M, Nagasaka A, Horimoto H, Yamamoto Y, Sakamoto N.
    A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
    Drugs R D. 2017 Sep;17(3):381-388. doi: 10.1007/s40268-017-0187-7. PMID: 28573606
  30. Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamsaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, Kumada T, Chayama K, Sakamoto N.
    Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    J Gastroenterol. 2018 Jan;53(1):119-128. doi:10.1007/s00535-017-1353-y. PMID:28560477
  31. Yoshikawa A, Terashita K, Morikawa K, Matsuda S, Yamamura T, Sarashina K, Nakano S, Kobayashi Y, Sogabe S, Takahashi K, Haba S, Oda H, Takahashi T, Miyagishima T, Sakamoto N.
    Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report.
    Clin J Gastroenterol. 2017 Jun; 10(3):270-273. doi: 10.1007/s12328-017-0742-3. PMID: 28447325
  32. Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ito J, Nakai M, Sho T, Natsuizka M, Morikawa K, Ogawa K, Sakamoto N.
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    J Hepatol. 2017 Nov;67(5):1106-1108. doi: 10.1016/j.jhep.2017.04.008. PMID: 28438688
  33. Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M, Umemura M, Ito J, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Tsubota A, Shimada N, Iio E, Tanaka Y, Sakamoto N; NORTE Study Group.
    Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    J Gastroenterol. 2017 Oct;52(10):1122-1129. doi: 10.1007/s00535-017-1328-z. PMID:　28315983
  34. Suda G, Ogawa K, Kimura M, Nakai M, Sho T, Morikawa K, Sakamoto N.
    Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.
    J Clin Transl Hepatol. 2016 Dec 28; 4(4):320-327. doi: 10.14218/JCTH.2016.00032. Review. PMID: 28097101
  35. Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus infected patients with renal impairment.
    Hepatol Res. 2017 Oct; 47(11):1127-1136. doi: 10.1111/hepr.12851. PMID: 27943523
  36. Morikawa K, Shimazaki T, Takeda R, Izumi T, Umumura M, Sakamoto N.
    Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection.
    Ann Transl Med. 2016 Sep; 4(18): 337. Review. PMID: 27761441
  37. Tsukuda Y, Suda G, Tsunematsu S, Ito J, Sato F, Terashita K, Nakai M, Sho T, Maehara O, Shimazaki T, Kimura M, Morikawa K, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Sakamoto N.
    Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection.
    J Med Virol. 2017 May; 89(5): 857-866. doi: 10.1002/jmv.24692. PMID: 27664407
  38. Tsunematsu S, Suda G, Yamasaki K, Kimura M, Izumi T, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Tanaka Y, Watashi K, Wakita T, Sakamoto N.
    Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.
    J Med Virol. 2017 Feb; 89(2): 267-275. doi: 10.1002/jmv.24643. PMID: 27459003
  39. Tsunematsu S, Suda G, Yamasaki K, Kimura M, Izumi T, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Kamiyama T, Taketomi A, Sakamoto N.
    Combination of neutrophil-to-lymphocyte ratio and early des-gamma-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma.
    Hepatol Res. 2017 May; 47(6):533-541. doi: 10.1111/hepr.12775. PMID: 27423140
  40. Ito J, Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kumagai K, Kikuchi H, Miyagishima T, Kobayashi T, Kimura M, Yamasaki K, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Terashita K, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
    Hepatol Res. 2016 Dec; 46(13): 1294-1303. doi: 10.1111/hepr.12685. PMID: 26896756
  41. Morikawa K, Suda G, Sakamoto N.
    Viral life cycle of hepatitis B virus: host factors and druggable targets.
    Hepatol Res. 2016 Aug; 46(9):871-7. doi: 10.1111/hepr.12650. Review. PMID: 26776362
  42. Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y, Ymasaki K, Kimura M, Umemura M, Izumi T, Tsunematsu S, Sato F, Terasita T, Nakai M, Horimoto H, Sho T, Natsuizka M, Morikawa K, Ogawa K, Sakamoto N.
    Efficacy and safety of daclatasvir and asnaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
    J Gastroenterol. 2016 Jul; 51(7):733-40. doi: 10.1007/s00535-016-1162-8. PMID: 26768604
  43. Maehara O, Sato F, Natsuizaka M, Asano A, Kubota Y, Itoh J, Tsunematsu S, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Chuma M, Nakagawa K, Ohnishi S, Komatsu Y, Whelan KA, Nakagawa H, Takeda H, Sakamoto N.
    A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma.
    Cancer Biol Ther. 2015; 16(10):1453-61. doi: 10.1080/15384047.2015.1070992. PMID: 26176896
  44. Hiraide A, Hiroishi K, Shimazaki T, Eguchi J, Ishii S, Morikawa K, Sakaki M, Doi H, Omori R, Kajiwara A, Hayashi E, Shiina M, Hirayama Y, Imawari M.
    Increased expression of immuno-inhibitory molecules on peripheral blood lymphocytes may suppress disease progression in autoimmune hepatitis.
    Hepatol Res. 2015 Nov; 45(11):1152-4. doi: 10.1111/hepr.12479. PMID: 25581267
  45. Tsunematsu S, Chuma M, Kamiyama T, Miyamoto N, Yabusaki S, Hatanaka K, Mitsuhashi T, Kamachi H, Yokoo H, Kakisaka T, Tsuruga Y, Orimo T, Wakayama K, Ito J, Sato F, Terashita K, Nakai M, Tsukuda Y, Sho T, Suda G, Morikawa K, Natsuizaka M, Nakanishi M, Ogawa K, Taketomi A, Matsuno Y, Sakamoto N.
    Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
    Abdom Imaging. 2015 Aug; 40(6):1492-9. doi: 10.1007/s00261-015-0352-9. PMID: 25579172
  46. Welsch C, Haselow K, Gouttenoire J, Schneider M, Morikawa K, Martinez Y, Susser S, Sarrazin C, Zeuzem S, Antes I, Moradpour D, Lange CM.
    Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β-induction by efficient MAVS cleavage.
    J Hepatol. 2015 Apr; 62(4):779-84. doi: 10.1016/j.jhep.2014.11.009. PMID: 25463536
  47. Lange CM, Gouttenoire J, Duong FH, Morikawa K, Heim MH, Moradpour D.
    Vitamin D Receptor and Jak-STAT Signaling Crosstalk Results in Calcitriol-Mediated Increase of Hepatocellular Response to IFN-α.
    J Immunol. 2014 Jun 15; 192(12):6037-44. doi: 10.4049/jimmunol.1302296. PMID: 24821973
  48. Morikawa K, Gouttenoire J, Hernandez C, Dao Thi VL, Tran HT, Lange CM, Dill MT, Heim MH, Donze O, Penin F, Quadroni M, Moradpour D.
    Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease.
    Hepatology. 2014 Feb; 59(2):423-33. doi: 10.1002/hep.26671. PMID: 23929719
  49. Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Mullhaupt B, Negro F, Semela D, Kutalik Z, Muller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY; Hiroshima Liver Study Group; Swiss Hepatitis C Cohort Study Group.
    Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development.
    PLoS One. 2013 May 29; 8(5):e64053. doi: 10.1371/journal.pone.0064053. PMID: 23734184
  50. Akazawa D, Moriyama M, Yokokawa H, Omi N, Watanabe N, Date T, Morikawa K, Aizaki H, Ishii K, Kato T, Mochizuki H, Nakamura N, Wakita T.
    Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Gastroenterology. 2013 Aug; 145(2):447-55. doi: 10.1053/j.gastro.2013.05.007. PMID: 23673355
  51. Date T, Kato T, Kato J, Takahashi H, Morikawa K, Akazawa D, Murayama A, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Wakita T.
    Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone.
    J Virol. 2012 Oct; 86(19): 10805-20. doi: 10.1128/JVI.07235-11. PMID: 22787209
  52. Inokuchi M, Ito T, Nozawa H, Miyashita M, Morikawa K, Uchikoshi M, Shimozuma Y, Arai J, Shimazaki T, Hiroishi K, Imawari M.
    Lymphotropic Hepatitis C Virus Has an Interferon-Resistant Phenotype.
    J Viral Hepat. 2012 Apr; 19(4):254-62. doi: 10.1111/j.1365-2893.2011.01541.x. PMID: 22404723
  53. Date T, Morikawa K, Tanaka Y, Tanaka-Kaneko K, Sata T, Mizokami M, Wakita T.
    Replication and infectivity of a novel genotype 1b hepatitis C virus clone.
    Microbiol Immunol. 2012 May; 56(5): 308-17. doi: 10.1111/j.1348-0421.2012.00437.x. PMID: 22320232
  54. Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, Dollenmaier G, Dufour JF, Gerlach TJ, Heim MH, Malinverni R, Mullhaupt B, Negro F, Moradpour D, Bochud PY; Swiss Hepatitis C Cohort Study Group.
    Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
    Hepatology. 2012 Apr; 55(4):1038-47. doi: 10.1002/hep.24787. PMID: 22095909
  55. Akazawa D, Morikawa K, Omi N, Takahashi H, Nakamura N, Mochizuki H, Date T, Ishii K, Suzuki T, Wakita T.
    Production and characterization of HCV particles from serum-free culture.
    Vaccine. 2011 Jun 24; 29(29-30):4821-8. doi: 10.1016/j.vaccine.2011.04.069. PMID: 21550372
  56. Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour D.
    Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.
    J Viral Hepat. 2011 May; 18(5):305-15. doi: 10.1111/j.1365-2893.2011.01451.x. Review. PMID: 21470343
  57. Inokuchi M, Ito T, Uchikoshi M, Shimozuma Y, Morikawa K, Nozawa H, Shimazaki T, Hiroishi K, Miyakawa Y, Imawari M.
    Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C.
    J Med Virol. 2009 Apr; 81(4):619-27. doi: 10.1002/jmv.21388. PMID: 19235854
  58. Doi H, Hiroishi K, Shimazaki T, Eguchi J, Baba T, Ito T, Matsumura T, Nozawa H, Morikawa K, Ishii S, Hiraide A, Sakaki M, Imawari M.
    Magnitude of CD8 T-cell responses against hepatitis C virus and severity of hepatitis do not necessarily determine outcomes in acute hepatitis C virus infection.
    Hepatol Res. 2009 Mar; 39(3):256-65. doi: 10.1111/j.1872-034X.2008.00459.x. PMID: 19054151
  59. Akazawa D, Date T, Morikawa K, Murayama A, Omi N, Takahashi H, Nakamura N, Ishii K, Suzuki T, Mizokami M, Mochizuki H, Wakita T.
    Characterization of infectious hepatitis C virus from liver-derived cell lines.
    Biochem Biophys Res Commun. 2008 Dec 19; 377(3):747-51. doi: 10.1016/j.bbrc.2008.10.063. PMID: 18951878
  60. Ishii K, Murakami K, Hmwe SS, Zhang B, Li J, Shirakura M, Morikawa K, Suzuki R, Miyamura T, Wakita T, Suzuki T.
    Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins.
    Biochem Biophys Res Commun. 2008 Jul 4; 371(3):446-50. doi: 10.1016/j.bbrc.2008.04.110. PMID: 18445476
  61. Aizaki H, Morikawa K, Fukasawa M, Hara H, Inoue Y, Tani H, Saito K, Nishijima M, Hanada K, Matsuura Y, Lai MM, Miyamura T, Wakita T, Suzuki T.
    Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection.
    J Virol. 2008 Jun; 82(12):5715-24. doi: 10.1128/JVI.02530-07. PMID: 18367533
  62. Murayama A, Date T, Morikawa K, Akazawa D, Miyamoto M, Kaga M, Ishii K, Suzuki T, Kato T, Mizokami M, Wakita T.
    The NS3 helicase and NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells.
    J Virol. 2007 Aug; 81(15):8030-40. PMID: 17522229
  63. Morikawa K, Zhao Z, Date T, Miyamoto M, Murayama A, Akazawa D, Tanabe J, Sone S, Wakita T.
    The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles.
    J Med Virol. 2007 Jun; 79(6):714-23. PMID: 17457918
  64. Date T, Miyamoto M, Kato T, Morikawa K, Murayama A, Akazawa D, Tanabe J, Sone S, Mizokami M, Wakita T.
    An infectious and selectable full-length replicon system with hepatitis C virus JFH-1 strain.
    Hepatol Res. 2007 Jun; 37(6):433-43. PMID: 17437527
  65. Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, Barth H, Baumert TF, Dubuisson J, Wakita T.
    CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection.
    J Virol. 2007 May; 81(10):5036-45. PMID: 17329343
  66. Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T.
    Cell culture and infection system for hepatitis C virus.
    Nat Protoc. 2006; 1(5):2334-9. PMID: 17406476
  67. Morikawa K, Ito T, Nozawa H, Inokuchi M, Uchikoshi M, Saito T, Mitamura K, Imawari M.
    Translational enhancement of HCV RNA genotype 1b by 3'-untranslated and envelope 2 protein-coding sequences.
    Virology. 2006 Feb 20; 345(2):404-15. PMID: 16289655
  68. Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, Mitamura K.
    Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Am J Gastroenterol. 2003 Jun; 98(6):1377-83. PMID: 12818284